Patients with indolent non-Hodgkin lymphomas (iNHL) report considerable psychological distress, according to a study published online Nov. 3 in The Oncologist.
Nov 21, 2023
0
1
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. ...
Oct 24, 2022
0
5
Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors. A new integrative, capture-based, next-generation sequencing (NGS) panel, ...
Jul 29, 2021
0
0
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response ...
Jan 8, 2020
0
15
People with follicular lymphoma, a slow-growing lymphatic-system cancer, who have been treated and are in remission for at least two years, may no longer have what has been considered an incurable disease based on highly ...
Dec 9, 2019
0
3
(HealthDay)—Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, according to a study published ...
Jul 25, 2019
0
1
(HealthDay)—Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and autologous T cells that express a CD19-directed CAR (CTL019) are effective for refractory B-cell ...
Dec 11, 2017
0
0
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) ...
Dec 10, 2017
0
0
An immunology discovery from the laboratories at the University of Southampton has now been shown to improve the outcomes of a common type of blood cancer in patients.
Nov 3, 2017
0
1
